Marcus D. Ballinger
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 39
- Cancer Immunotherapy and Biomarkers 31
- CAR-T cell therapy research 4
- Colorectal Cancer Treatments and Studies 4
-
- Immunotherapy and Immune Responses 3
- Immune Cell Function and Interaction 3
- Co-authors
- Alan Sandler (7 shared papers)Achim Rittmeyer (8 shared papers)Keunchil Park (5 shared papers)Daniel S. Chen (3 shared papers)Julien Mazières (4 shared papers)David C. Smith (2 shared papers)Pei He (3 shared papers)Marcin Kowanetz (3 shared papers)
- Journals
- Biochemistry (7 papers)Journal of Thoracic Oncology (7 papers)Clinical Lung Cancer (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)The Lancet (3 papers)
- Partner nations
- United StatesFranceSwitzerland
In The Last Decade
Marcus D. Ballinger
55 papers receiving 13.0k citations
Marcus D. Ballinger's Hit Papers
Peers
Comparison fields: 5 of 116
- Oncology 8.7k
- Pulmonary and Respiratory Medicine 3.9k
- Immunology 2.4k
- Cancer Research 1.4k
- Radiology, Nuclear Medicine and Imaging 779
Countries citing papers authored by Marcus D. Ballinger
This map shows the geographic impact of Marcus D. Ballinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus D. Ballinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus D. Ballinger more than expected).
Fields of papers citing papers by Marcus D. Ballinger
This network shows the impact of papers produced by Marcus D. Ballinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus D. Ballinger. The network helps show where Marcus D. Ballinger may publish in the future.
Co-authors
The 25 scholars most cited alongside Marcus D. Ballinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Hit paper breakdown → | 2016 | 3949 |
| 2 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Hit paper breakdown → | 2016 | 2372 |
| 3 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Hit paper breakdown → | 2017 | 1874 |
| 4 | Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab Hit paper breakdown → | 2018 | 947 |
| 5 | Peripheral T cell expansion predicts tumour infiltration and clinical response Hit paper breakdown → | 2020 | 579 |
| 6 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 473 |
| 7 | Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer Hit paper breakdown → | 2022 | 309 |
| 8 | 2018 | 280 | |
| 9 | 2018 | 214 | |
| 10 | 2019 | 199 | |
| 11 | 2018 | 197 | |
| 12 | 1991 | 157 | |
| 13 | 2018 | 144 | |
| 14 | 2020 | 134 | |
| 15 | 2018 | 118 | |
| 16 | 1992 | 80 | |
| 17 | 2019 | 75 | |
| 18 | 2009 | 68 | |
| 19 | 2019 | 67 | |
| 20 | 2018 | 63 |
About Marcus D. Ballinger
Marcus D. Ballinger is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Cancer Research, having authored 55 papers that have together received 13.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (31 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer Genomics and Diagnostics (4 papers), CAR-T cell therapy research (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Immunotherapy and Immune Responses (3 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Oncology (8.7k citations), Pulmonary and Respiratory Medicine (3.9k citations), Immunology (2.4k citations), Cancer Research (1.4k citations) and Radiology, Nuclear Medicine and Imaging (779 citations). Marcus D. Ballinger has collaborated with scholars based in United States, France and Switzerland. Frequent co-authors include Alan Sandler, Achim Rittmeyer, Keunchil Park, Daniel S. Chen, Julien Mazières, David C. Smith, Pei He, Marcin Kowanetz, Frank Stephen Hodi and Wei Zou. Their work appears in journals such as Biochemistry, Journal of Thoracic Oncology, Clinical Lung Cancer, Journal for ImmunoTherapy of Cancer and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.